

March 30, 2020

## **ONO Enters into a New Research and Option Agreement with Numab**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director and CEO, Gyo Sagara; “Ono”) announced today that it entered into another research and option agreement with Numab Therapeutics AG (Waedenswil, Switzerland; CEO, David Urech; “Numab”) to discover and develop a multi-specific antibody drug candidate for the treatment of various cancers.

Ono previously concluded a research and option agreement with Numab in March 2017. The agreement executed this time is to discover an antibody binding to a combination of multiple discovery targets different from the earlier agreement. Similar to their earlier collaboration, under this new agreement, Ono has obtained an option to acquire from Numab worldwide exclusive rights to develop and commercialize an immuno-oncology drug candidate that will leverage Numab’s platform technology in order to actualize one of Ono’s novel therapeutic approaches. In exchange, ONO will pay to Numab up to CHF 260 million in upfront and milestone payments plus tiered single to double digit royalties on sales.

“The capabilities of Numab’s multi-specific antibody platform which is robust and optimized to reproducibly yield product candidates with outstanding binding properties have been confirmed through the existing collaboration,” said Toichi Takino, Corporate Executive Officer, and Executive Director of Discovery & Research of Ono. “We believe that a multi-specific antibody to be generated through this collaboration will provide hope to sufferers of cancer.”

“Today’s announcement signals a mutual recognition of the quality and expertise that both parties have contributed under our earlier, ongoing agreement. Ono’s decision to enter another agreement based on Numab’s technology is a clear validation of our platform and highlights their commitment to include multi-specific antibodies as major component of their pipeline strategy in oncology,” commented Dr. Oliver Middendorp, Chief Business Officer of Numab. “In addition to ND023, which was initiated under our original agreement, we are excited to collaborate with Ono on yet another truly differentiated mechanism of action with this new project.”

### **About Numab Therapeutics**

Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit [www.numab.com](http://www.numab.com).

Contact  
ONO PHARMACEUTICAL CO., LTD.  
Corporate Communications  
[public\\_relations@ono.co.jp](mailto:public_relations@ono.co.jp)